Atyr Pharma, Inc.

Pangu Biopharma Limited

Other

Fate Therapeutics, Inc.

Bristol-myers Squibb Compnay

Aurora Biosciences Corporation

Affinium Pharmaceuticals, Inc.

Atye Pharma, Inc.

Pangu Bigpharma Limited

Pangn Biopharma Limited

John D Mendlein

Kyle P Chiang

Jeffry Dean Watkins

Alain Philippe Vasserot

Leslie Ann Greene

Wing-Sze Lo

Cheryl L Quinn

Fei Hong

Philipp K Lang

Roger Y Tsien

Eric Steven Furfine

Ying Buechler

Chi-Fang Wu

Kristi Helen Piehl

Minh-Ha Do

Darin Lee

David Robbins

Marc Thomas

Jeffrey M Greve

Ray Camphausen

Martin C Wright

David Fabrizio

Zhiwen Xu

Caroline Desponts

Dan Shoemaker

Patrick Gage

Daniel D Shoemaker

Ryan Andrew Adams

Jeffrey D Watkins

Ching-Fun Lau

Pratik S Multani

Melissa Ashlock

Elisabeth Gardiner

Charles S Zuker

Peter J Coassin

Alec Tate Harootunian

Andrew A Pham

Judd Berman

David L Robbins

Molly B Schmid

Kathleen Ogilvie

Nachum Kaplan

Stephan Grampp

Paul Grayson

Alian P Vasserot

Ching Fun Lau

Jimena Sierralta

Susan Tsunoda

Yumei Sun

Judd M Berman

Pratik Multani

Kristi Piehl

Martin C Wrigt

Provided are therapies, including combination therapies, for the treatment of lung inflammation, including interstitial lung diseases (ILDs), which include the use of at least one histidyl-tRNA synthetase (HRS) polypeptide or an expressible polynucleotide that encodes the HRS polypeptide, alone or in combination with at least one immunomodulatory agent.

Compositions and methods for treating lung inflammation

The present invention provides innovative proteins that bind to insulin-like growth factor-I receptor (IGF-IR), as well as other important proteins. The invention also provides innovative proteins in pharmaceutical preparations and derivatives of such proteins and the uses of same in diagnostic, research and therapeutic applications. The invention further provides cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins.

Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR

The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.

Histidyl-tRNA synthetase-Fc conjugates

The invention provides improved methods for cell therapy. In particular, the invention provides therapeutic compositions of enhanced hematopoietic stem and progenitor cells having improved engraftment and homing properties, and methods of making the therapeutic compositions. The invention further provides methods of improving the efficacy of hematopoietic stem and progenitor cell transplantation including transplanting the therapeutic composition to subjects in need of hematopoietic system reconstitution.

Enhanced stem cell composition

The invention provides compositions comprising stem and/or progenitor cells that have been treated to enhance the therapeutic properties of the cells for treating ischemia. In particular, the present invention relates to the use of stem and/or progenitor cells having enhanced therapeutic properties to treat an ischemic tissue, a tissue damaged by ischemia, or at least one symptom associated with an ischemic tissue or a tissue damaged by ischemia.

Methods of treating ischemia

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Cysteinyl-tRNA synthetase

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Histidyl-tRNA synthetases

Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of tryptophanyl tRNA synthetases

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl-tRNA synthetases

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-tRNA synthetases

Methods of treating cancer by administering IGF-IR binding molecules

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-tRNA synthetases

Growing community of inventors

Encinitas, CA, United States of America

John D Mendlein